Viewing Study NCT02652468


Ignite Creation Date: 2025-12-24 @ 5:33 PM
Ignite Modification Date: 2026-04-05 @ 1:27 AM
Study NCT ID: NCT02652468
Status: COMPLETED
Last Update Posted: 2022-01-05
First Post: 2016-01-05
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
Sponsor: University of Wisconsin, Madison
Organization:

Study Overview

Official Title: A Pilot Study to Assess Engraftment Using CliniMACS TCR-α/β and CD19 Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Progenitor Cell Transplantation (HSCT) in Patients With Relapsed Lymphoma
Status: COMPLETED
Status Verified Date: 2021-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To determine engraftment of neutrophils and platelets at 28 days following alpha/beta T-cell and CD19 cell depletion using Human Leukocyte Antigen (HLA) haploidentical donors for peripheral blood stem cell transplant in relapsed lymphoma.

Assess incidence of acute Graft Versus Host Disease (GVHD), chronic GVHD, graft failure rate, treatment related mortality rate, progression free survival and overall survival of patients.

The stem cell product will be processed using an investigational Miltenyi cell selection device/system that removes the alpha/beta T-cells and CD19+ cells, immune system cells that are more likely to cause GVHD.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2015-0996 OTHER IRB View
NCI-2015-02269 REGISTRY NCI Trial ID View
A534260 OTHER UW Madison View
SMPH\MEDICINE\HEM-ONC OTHER UW Madison View
Protocol Version 4/24/2020 OTHER UW Madison View